VERTIS-CV trial of SGLT2 inhibitor evaluated medication’s cardiovascular safety in patients with type 2 diabetes and heart disease The
Published: Tuesday, June 16, 2020
Give Today and Change lives!
With your support, the American Diabetes Association® can continue our lifesaving work to make breakthroughs in research and provide people with the resources they need to fight diabetes.